New partnerships and study collaborations, the events where you'll find us, and our thinking on tumour-informed ctDNA and where it's taking cancer care.
Showing posts tagged corporate. Clear filter
Image: Solar Egg, Bigert & Bergström. Photo – Johan Strindberg Ahead of Momentum in Stockholm this October, a note on one lever for faster uptake …
Cancer services across the Nordics are under familiar pressure: rising incidence, tighter staffing, constrained imaging capacity, and a growing expect…
Simsen Diagnostics Partners with One-carbon Therapeutics for Groundbreaking ODIN Cancer Trial Simsen Diagnostics, a leader in ultra-sensitive analysis…
Developing effective cancer treatments is one of the most challenging frontiers in drug development, where precision, timing, and sensitivity can dram…
Simsen Diagnostics is excited to announce our participation in the upcoming GoCo Investor Day, a leading gathering for innovation, investment, and col…
We are proud to announce a new partnership with a Swedish hospital, paving the way for transformative advancements in personalised cancer care. This c…
We are pleased to announce that our CEO, Pontus Rehn, will represent Simsen Diagnostics at the upcoming Ecosystem Exchange: Life Sciences 2025, hosted…
Simsen Diagnostics is excited to announce its participation in the upcoming Swiss Nordic Bio 2025 conference, which will take place in Zurich on March…
Gothenburg 2024-10-25: Simsen Diagnostics has signed an agreement with Docrates, a private cancer center in Finland. The agreement allows Docrates to …
As we approach summer and vacations (at least for some of us in the office and most industry people here in Sweden), we wanted to take a moment to loo…
Gothenburg 2024-04-23 – Simsen Diagnostics announces having received a Vinnova grant through the strategic innovation program Swelife to strengthen Li…
Tell us about your study and your endpoints. A real scientist in CET/CEST will reply.
